This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Viral Infections  • Sweating  • Dermatologic Disorders, Other  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

My coauthors and I appreciate the positive response to our study on intralesional lipolysis, and we share the opinion of Dr Bechara and colleagues that monotherapy with injections of PTC is unable to completely erase lipomas.¹ In some patients, size reduction of grossly 50% of the pretreatment volume offers sufficient relief from the disturbance. The fact that it may be easier for surgeons to remove lipomas after 3 or more intralesional injections of PTC—perhaps by means of the "squeeze delivery" technique—supports the feasibility of this treatment option.²

Still, at this stage, intralesional lipolysis cannot be recommended as a standard procedure. Recurrence rates, recommended dosage, and remaining uncertainties should be carefully studied before this method is used for the reduction of lipomas and for fat reduction for aesthetic purposes. Further controlled clinical trials are necessary to create an evidence-based scientific background for intralesional application of PTC formulations.

AUTHOR INFORMATION
Correspondence: Dr . . . [Full Text of this Article]

Daisy Kopera, MD

RELATED ARTICLE

Intralesional Lipolysis With Phosphatidylcholine for the Treatment of Lipomas: Pilot Study
Falk G. Bechara, Michael Sand, Peter Altmeyer, and Klaus Hoffmann
Arch Dermatol. 2006;142(8):1069-1070.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Drug-Induced Sweet's Syndrome
Thompson and Montarella
The Annals of Pharmacotherapy 2007;41:802-811.
ABSTRACT | FULL TEXT